共 50 条
- [1] Pharmacokinetics (PK) and Immunogenicity of Linvoseltamab in Patients (pts) with Relapsed/ Refractory Multiple Myeloma (RRMM) in LINKER-MM1CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S57 - S57Hazra, AnasuyaLai, Ching-HaChokshi, DhrutiHouvras, YarivKroog, Glenn S.Lorenc, Karen RodriguezDiCioccio, A. ThomasDavis, John
- [2] Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 studyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S172 - S172Dhodapkar, MadhavBumma, NareshRichter, JoshuaLee, HansHoffman, JamesSuvannasankha, AttayaLentzsch, SuzanneShah, MansiZonder, JeffreyBaz, RachidWu, Ka LungPianko, MatthewSilbermann, RebeccaMin, Chang-KiVekemans, Marie-Christiane MadeleineMunder, MarkusByun, Ja MinMartinez Lopez, JoaquinDeVeaux, MichelleLorenc, Karen RodriguezKroog, GlennHouvras, YarivJagannath, Sundar
- [3] Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S90 - S91Suvannasankha, AttayaLee, HansBumma, NareshDhodapkar, Madhav V.Richter, JoshuaHoffman, James E.Shah, MansiLentzsch, SuzanneZonder, JeffreyBaz, RachidMaly, Joseph J.Namburi, SwathiWu, Ka LungPianko, MatthewSilbermann, RebeccaMin, Chang-KiVekemans, Marie-ChristianeMunder, MarkusMartinez Lopez, JoaquinDeVeaux, MichelleChokshi, DhrutiBoyapati, AnitaKroog, Glenn S.Houvras, YarivJagannath, Sundar
- [4] Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 StudyBLOOD, 2023, 142Jagannath, SundarRichter, JoshuaDhodapkar, Madhav V.Hoffman, James E.Lee, Hans C.Suvannasankha, AttayaShah, Mansi R.Lentzsch, SuzanneZonder, Jeffrey A.Baz, RachidMaly, Joseph J.Namburi, SwathiWu, Ka LungPianko, MatthewYe, Jing ChristineSilbermann, RebeccaMin, Chang-KiVekemans, Marie-ChristianeMunder, MarkusByun, Ja Min
- [5] Assessment of health-related quality of life (HRQoL) in triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Hoffman, James E.Bumma, NareshRichter, Joshua RyanDhodapkar, Madhav V.Lee, Hans C.Suvannasankha, AttayaZonder, Jeffrey A.Maly, Joseph J.Shah, Mansi R.Baz, Rachid C.DeVeaux, MichelleIvanescu, CristinaRodriguez-Lorenc, KarenKroog, Glenn ScottHouvras, Yariv J.Inocencio, Timothy J.Chi, LeiHarnett, JamesMa, QiufeiJagannath, Sundar
- [6] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2020, 136Madduri, DeepuRosko, AshleyBrayer, JasonZonder, JeffreyBensinger, William I.Li, JingjinXu, LinzhiAdriaens, LieveChokshi, DhrutiZhang, WeijiangBoyapati, AnitaSharma, ManishSeebach, FrankSirulnik, L. AndresWeinreich, David M.Yancopoulos, George D.Dhodapkar, Madhav V.Lentzsch, SuzanneCooper, DennisJagannath, Sundar
- [7] Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human StudyBLOOD, 2022, 140 : 10140 - 10141Bumma, NareshRichter, JoshuaBrayer, JasonZonder, Jeffrey A.Dhodapkar, MadhavShah, Mansi R.Hoffman, James E.Mawad, RayaMaly, Joseph J.Lentzsch, SuzanneSuvannasankha, AttayaRoy, PourabDey, JyotirmoyChokshi, DhrutiBoyapati, AnitaVisich, JennHouvras, YarivLorenc, Karen RodriguezKroog, Glenn S.Jagannath, Sundar
- [8] Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2022, 140 : 4444 - 4446Rodriguez Otero, PaulaJoseph, Nisha S.Kumar, Shaji K.Lee, Hans C.Leleu, XavierManier, SalomonDimopoulos, Meletios A.Victoria Mateos, MariaOriol, AlbertBumma, NareshGong, WeiyingRoy, PourabLorenc, Karen RodriguezKroog, Glenn S.Sarkaria, Shawn M.
- [9] Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2019, 134Cooper, DennisMadduri, DeepuLentzsch, SuzanneJagannath, SundarLi, JingjinBoyapati, AnitaAdriaens, LieveChokshi, DhrutiZhu, MinLowy, IsraelWeinreich, David M.Yancopoulos, George D.Sharma, ManishKarasarides, MariaSternberg, David
- [10] Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S35Zonder, JeffreyRichter, JoshuaBumma, NareshBrayer, JasonHoffman, James E.Bensinger, William I.Wu, Ka LungXu, LinzhiChokshi, DhrutiBoyapati, AnitaCronier, DamienHouvras, YarivLorenc, Karen RodriguezKroog, Glenn S.Dhodapkar, Madhav V.Lentzsch, SuzanneCooper, DennisJagannath, Sundar